We examined the effects of nicainoprol (1-50 microM), a new antiarrhythmic agent, on the transmembrane action potentials in isolated papillary muscles of the guinea pig. Nicainoprol (greater than or equal to 5 microM) produced dose-dependent decreases in the maximal upstroke velocity (Vmax) of the action potential. Only the highest concentration (50 microM) decreased the amplitude and the overshoot of the action potential and shortened its duration at 50 or 90% repolarization levels (APD50, APD90). The potential at rest was not affected by any concentration tested (1-50 microM). In the presence of nicainoprol, trains of stimuli at the rate of 0.2, 0.5, 1.0, and 2.0 Hz, introduced after a sufficient period of rest, led to an exponential decay of the Vmax to the steady state levels (use-dependent block, UDB). The UDB was augmented with an increase in the stimulation frequency or with a decrease in the potentials at rest. The time constant for the recovery from the UDB was 51.6 +/- 9.4 s at 50 microM. The Vmax and the amplitude of the slow response elicited in the presence of 27 mM [K+]o and 0.2 mM Ba2+ was significantly decreased by application of nicainoprol (10-100 microM), with a significant shortening of APD50 (100 microM). These findings suggest that nicainoprol has electrophysiologic properties in common with those of other class I antiarrhythmic drugs with slow kinetics (Ic) and has a minor but significant inhibitory effect on slow inward current (class IV effect).

Download full-text PDF

Source

Publication Analysis

Top Keywords

effects nicainoprol
8
class antiarrhythmic
8
antiarrhythmic agent
8
guinea pig
8
1-50 microm
8
action potential
8
microm
7
nicainoprol
6
electrophysiologic effects
4
nicainoprol putative
4

Similar Publications

1. The electrophysiological effects of a series of drugs with Class I antiarrhythmic activity were examined in sheep Purkinje fibres, superfused in vitro with either a normal or hypoxic, hyperkalaemic and acidotic physiological salt solution (PSS). 2.

View Article and Find Full Text PDF

One hundred and three patients with a history of ventricular arrhythmia were screened by baseline 24-h Holter monitoring for a minimal mean number of 30 premature ventricular beats (PVB) per hour. One hundred and one patients were subsequently enrolled in a double-blind, cross-over trial, including four 4-day periods with administration of placebo (PL) or nicainoprol (N.) in doses of 200, 400, 600 mg three times daily in randomized order.

View Article and Find Full Text PDF

The antiarrhythmic and direct cardiovascular effects of a new antiarrhythmic agent, TYB-3823 [1-(2,6-dimethylphenyl)-4,4-dimethyl-aminoguanidine hydrochloride], were investigated. To determine the antiarrhythmic effects, spontaneously occurring adrenaline-, digitalis-, and two-stage coronary ligation-induced arrhythmias were used. TYB-3823 suppressed these three arrhythmia models.

View Article and Find Full Text PDF

The electrophysiological effects of nicainoprol, a new class I antiarrhythmic drug, were evaluated in 29 patients with supraventricular reentrant tachycardias, due to accessory pathways in 15 and dual atrioventricular nodal pathways in 14 patients. Nicainoprol was administered intravenously as a bolus followed by continuous infusion of 1.5 mg/kg in two and of 2 mg/kg in 27 patients over one hour.

View Article and Find Full Text PDF

We investigated the influence of the angiotensin-converting enzyme (ACE) inhibitor ramipril on cardiac arrhythmias in guinea pigs and rats. Ramiprilat, the active moiety of ramipril, did not influence action potentials of isolated guinea-pig papillary muscle or rabbit sinus node, thereby excluding cellular electrophysiological evidence of anti-arrhythmic properties. Ramipril protected against cardiac arrhythmias induced by digoxin infusion in guinea pigs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!